EUVIMEDEUVIMED entdecken
Multizentrische StudieQuerschnittstudie

Serum calprotectin as a biomarker for large vessel vasculitis: a multicenter cross-sectional study

Sidar Çöpür, Ayşegül Avcu, Nagehan Dik Kutlu, Fatma Dilara Yuruk Kitay, Pınar Akyüz Dağlı, Muhammet Emin Kutu, Burcu Ceren Uludoğan, Said İncir, Erhan Palaoğlu, Yavuz Pehlivan, Cemal Bes, Ahmet Omma und 5 weitere

International Immunopharmacology · 2026

DOI: 10.1016/j.intimp.2026.117205 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Sidar Çöpür und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Koc University Faculty of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Giant Cell Arteritis, Takayasu Arteritis. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Siemens Healthineers USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Large vessel vasculitis (LVV), namely Takayasu arteritis (TAK) and giant cell arteritis (GCA), is the most common type of primary vasculitis affecting adult patients with significant and potentially debilitating consequences. Even though C-reactive protein (CRP) and erythrocyte sedimentation rate are widely utilized biochemical markers for disease activity among LVV patients, such biomarkers are not without major drawbacks, especially with the more widespread use of anti-interleukin-6 based therapies. METHODS: We have conducted a multicentered, cross-sectional cohort study involving a total of 149 LVV patients with 183 clinical visits from seven tertiary care centers with specialized rheumatology clinics. RESULTS: A total of 42 GCA and 107 TAK patients with a mean age of 51.2 (±18.04) years and female predominance have been included in our study while 14.1% of the patients were classified as in active disease state. We have failed to demonstrate a statistically significant association between serum calprotectin levels and disease activity states among LVV patients 1.65 (1.15-2.08) vs 1.26 (0.65-1.81) μg/mL, p = 0.077), the GCA subgroup (1.65 (1.47-1.70) vs 0.88 (0.59-1.75) μg/mL, p = 0.136), or the TAK subgroup (1.73 (0.86-2.08) vs 1.32 (0.92-1.77) μg/mL, p = 0.466). In contrast, CRP was significantly higher in active disease in the overall cohort (7.13 (0.56-21.70) vs 2.60 (0.84-6.58) mg/L, p = 0.044) and in the GCA subgroup (14.75 (6.97-19.80) vs 1.44 (0.50-6.00) mg/L, p = 0.039), but not in the TAK subgroup (p = 0.162). CONCLUSION: Our large-scale multicentered cohort study has failed to demonstrate superiority of serum calprotectin assay in the assessment of disease activity among LVV patients. With the growing use of numerous biological agents in LVV treatment, the need for a reliable biomarker with strong discriminative power still continues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte L1 Antigen ComplexGiant Cell ArteritisTakayasu ArteritisHumansFemaleCross-Sectional StudiesBiomarkersMaleMiddle AgedAgedAdultC-Reactive Protein

Stichwörter der Autor:innen

CalprotectinGiant cell arteritisLarge vessel vasculitisTakayasu arteritis

Substanzen

Leukocyte L1 Antigen ComplexBiomarkersC-Reactive Protein

Autor:innen und Institutionen

  • Department of Internal Medicine, Koc University Faculty of Medicine, Istanbul, Turkey.
  • Department of Internal Medicine, Division of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey.
  • Department of Internal Medicine, Division of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey.
  • Department of Internal Medicine, Division of Rheumatology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
  • Department of Internal Medicine, Division of Rheumatology, University of Health Sciences Ankara City Hospital, Ankara, Turkey.
  • Department of Internal Medicine, Division of Rheumatology, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Förderung

  • Siemens Healthineers USA

Zitieren

APA

Çöpür, S., Avcu, A., Dik Kutlu, N., Yuruk Kitay, F. D., Akyüz Dağlı, P., Kutu, M. E., Uludoğan, B. C., İncir, S., Palaoğlu, E., Pehlivan, Y., Bes, C., Omma, A., Erten, Ş., Yaşar Bilge, N. Ş., Alibaz Oner, F., Direskeneli, H., & Alpay Kanıtez, N. (2026). Serum calprotectin as a biomarker for large vessel vasculitis: a multicenter cross-sectional study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117205

Vancouver

Çöpür S, Avcu A, Dik Kutlu N, Yuruk Kitay FD, Akyüz Dağlı P, Kutu ME, et al. Serum calprotectin as a biomarker for large vessel vasculitis: a multicenter cross-sectional study. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.117205

BibTeX
@article{pr2026,
  author = {Çöpür, Sidar and Avcu, Ayşegül and Dik Kutlu, Nagehan and Yuruk Kitay, Fatma Dilara and Akyüz Dağlı, Pınar and Kutu, Muhammet Emin and Uludoğan, Burcu Ceren and İncir, Said and Palaoğlu, Erhan and Pehlivan, Yavuz and Bes, Cemal and Omma, Ahmet and Erten, Şükran and Yaşar Bilge, Nazife Şule and Alibaz Oner, Fatma and Direskeneli, Haner and Alpay Kanıtez, Nilüfer},
  title = {Serum calprotectin as a biomarker for large vessel vasculitis: a multicenter cross-sectional study},
  journal = {International Immunopharmacology},
  year = {2026},
  doi = {10.1016/j.intimp.2026.117205}
}
Kostenlos starten →